A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 06 Aug 2017
At a glance
- Drugs ALKS 8700 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Acronyms EVOLVE-1; EVOLVE-MS-1
- Sponsors Alkermes plc
- 02 Jun 2017 Planned number of patients changed from 800 to 935.
- 28 Apr 2017 Trial design presented at the 69th Annual Meeting of the American Academy of Neurology
- 13 Feb 2017 Planned number of patients changed from 600 to 800.